|
IL138214A0
(en)
*
|
1998-03-09 |
2001-10-31 |
Zealand Pharmaceuticals As |
Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US7550425B2
(en)
|
2000-06-16 |
2009-06-23 |
Zealand Pharma A/S |
Diuretic peptide conjugates
|
|
WO2006045503A1
(en)
|
2004-10-19 |
2006-05-04 |
Lonza Ag |
Method for solid phase peptide synthesis
|
|
AU2006242998B2
(en)
|
2005-05-04 |
2012-03-22 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
|
GB0514071D0
(en)
|
2005-07-07 |
2005-08-17 |
Zealand Pharma As |
N- or C- terminally modified small peptides
|
|
JPWO2007060860A1
(ja)
*
|
2005-11-22 |
2009-05-07 |
学校法人日本大学 |
ピロールイミダゾールポリアミドの固相自動合成
|
|
CN101336229B
(zh)
|
2005-12-23 |
2012-06-13 |
西兰岛药物有限公司 |
改性的拟赖氨酸化合物
|
|
EP1991560B1
(en)
*
|
2006-02-20 |
2018-04-04 |
Ewha University-Industry Collaboration Foundation |
Peptide having cell membrane penetrating activity
|
|
CA2647867C
(en)
*
|
2006-03-29 |
2015-11-03 |
Otsuka Chemical Co., Ltd. |
Method for production of peptide thioester compound
|
|
EP2051995B1
(en)
|
2006-11-08 |
2017-02-08 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (glp-2) analogues
|
|
EP2158214B1
(en)
|
2007-06-15 |
2011-08-17 |
Zealand Pharma A/S |
Glucagon analogues
|
|
JP5635530B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
DK2370461T3
(da)
|
2008-12-15 |
2013-12-16 |
Zealand Pharma As |
Glucagonanaloger
|
|
BRPI0823377A2
(pt)
|
2008-12-15 |
2016-09-27 |
Zealand Pharma As |
análogos de glucagon
|
|
MA32970B1
(fr)
|
2008-12-15 |
2012-01-02 |
Zealand Pharma As |
Analogues du glucagon
|
|
JP6054742B2
(ja)
|
2009-07-13 |
2016-12-27 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
|
JP5969461B2
(ja)
|
2010-04-27 |
2016-08-17 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
|
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
US9169310B2
(en)
|
2010-06-24 |
2015-10-27 |
Zealand Pharma A/S |
Glucagon analogues
|
|
PH12013501495A1
(en)
|
2011-01-20 |
2013-09-16 |
Zealand Pharma As |
Combination of acylated glucagon analogues with insulin analogues
|
|
CN104144704B
(zh)
|
2011-11-03 |
2018-03-23 |
西兰制药公司 |
Glp‑1受体激动剂肽胃泌素缀合物
|
|
SG11201403377QA
(en)
|
2011-12-23 |
2014-07-30 |
Zealand Pharma As |
Glucagon analogues
|
|
WO2013098408A1
(en)
|
2011-12-30 |
2013-07-04 |
Zealand Pharma A/S |
Glucagon and cck receptor agonist peptide conjugates
|
|
TW201336864A
(zh)
|
2012-02-03 |
2013-09-16 |
Zealand Pharma As |
胃飢餓素(ghrelin)類似物
|
|
EP2844670B1
(en)
|
2012-05-03 |
2017-12-06 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
|
JP6228187B2
(ja)
|
2012-05-03 |
2017-11-08 |
ジーランド ファーマ アクティーゼルスカブ |
Gip−glp−1デュアルアゴニスト化合物及び方法
|
|
MX356957B
(es)
|
2012-07-23 |
2018-06-20 |
Zealand Pharma As |
Analogos del glucagon.
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
CN105051067B
(zh)
|
2013-03-12 |
2020-04-17 |
分子模板公司 |
用于引起细胞内化的cd20结合免疫毒素及其使用方法
|
|
US9169287B2
(en)
|
2013-03-15 |
2015-10-27 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
|
US9695214B2
(en)
|
2013-03-15 |
2017-07-04 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
|
DK2976325T3
(en)
|
2013-03-21 |
2017-06-06 |
Sanofi Aventis Deutschland |
SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID
|
|
AU2014234400B2
(en)
|
2013-03-21 |
2017-11-16 |
Sanofi-Aventis Deutschland Gmbh |
Synthesis of hydantoin containing peptide products
|
|
CA2926314C
(en)
|
2013-10-17 |
2023-08-29 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
CN105829339B
(zh)
|
2013-11-06 |
2021-03-12 |
西兰制药公司 |
胰高血糖素-glp-1-gip三重激动剂化合物
|
|
AU2014345569B2
(en)
|
2013-11-06 |
2020-08-13 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
|
US10435474B2
(en)
|
2013-12-24 |
2019-10-08 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
|
KR102500408B1
(ko)
|
2014-01-27 |
2023-02-16 |
몰레큘러 템플레이츠, 인코퍼레이션. |
포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드
|
|
PL3604333T3
(pl)
|
2014-03-11 |
2021-11-08 |
Molecular Templates, Inc. |
Białka zawierające regiony efektorowe podjednostki a toksyny shiga proksymalnie do końca aminowego oraz celujące w komórki regiony wiążące typu immunoglobuliny zdolne do swoistego wiązania cd38
|
|
US20170002046A1
(en)
|
2014-03-11 |
2017-01-05 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
|
CN113831416A
(zh)
|
2014-06-11 |
2021-12-24 |
分子模板公司 |
耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
|
|
WO2015200883A2
(en)
|
2014-06-26 |
2015-12-30 |
Ossianix, Inc. |
Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
|
|
EP3212218B1
(en)
|
2014-10-29 |
2021-06-30 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
|
WO2016077840A2
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
|
|
ES2856457T3
(es)
|
2015-02-05 |
2021-09-27 |
Molecular Templates Inc |
Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas
|
|
JP6769984B2
(ja)
|
2015-03-18 |
2020-10-14 |
ジーランド ファーマ アクティーゼルスカブ |
アミリン類似体
|
|
GB201506380D0
(en)
|
2015-04-15 |
2015-05-27 |
Serodus Asa |
Materials and methods for treatment of pulmonary hypertension
|
|
CA2980978A1
(en)
|
2015-04-16 |
2016-10-20 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
|
CN107849096B
(zh)
|
2015-05-30 |
2022-05-24 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
|
AU2016297920A1
(en)
|
2015-07-26 |
2018-01-18 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
|
|
CN108290923A
(zh)
|
2015-09-17 |
2018-07-17 |
麻省理工学院 |
用于固相肽合成的方法和系统
|
|
US11097010B2
(en)
|
2016-08-06 |
2021-08-24 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
US10071140B2
(en)
|
2016-09-09 |
2018-09-11 |
Zealand Pharma A/S |
Amylin analogues
|
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
BR112019011859A2
(pt)
|
2016-12-09 |
2019-10-29 |
Zealand Pharma As |
agonista duplo de glp-1/glp-2, composição, método para aumentar massa intestinal, método de profilaxia ou tratamento de má-absorção intestinal e uso de um agonista duplo
|
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
RU2753193C2
(ru)
|
2016-12-09 |
2021-08-12 |
Зилэнд Фарма А/С |
Ацилированные двойные агонисты glp-1/glp-2
|
|
MX2019008840A
(es)
|
2017-01-25 |
2019-09-09 |
Molecular Templates Inc |
Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
|
|
ES2894629T3
(es)
|
2017-06-16 |
2022-02-15 |
Zealand Pharma As |
Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
|
|
CA3080351A1
(en)
|
2017-11-02 |
2019-05-09 |
Ossianix, Inc. |
Improved tfr-selective binding peptides capable of crossing the blood brain barrier
|
|
JP7690287B2
(ja)
|
2018-02-27 |
2025-06-10 |
セトペー エスペーベー 3 コマンディト セルスカブ |
コンプスタチン類似体及びその医療用途
|
|
AU2019257343A1
(en)
|
2018-04-17 |
2020-09-10 |
Molecular Templates, Inc. |
HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
|
|
US12258414B2
(en)
|
2018-06-22 |
2025-03-25 |
Ossianix, Inc. |
Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
|
|
CA3100035A1
(en)
|
2018-08-27 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Use of raman spectroscopy in downstream purification
|
|
US12351642B2
(en)
|
2018-09-14 |
2025-07-08 |
Ossianix, Inc. |
TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
EP3914358A1
(en)
|
2019-01-23 |
2021-12-01 |
Millennium Pharmaceuticals, Inc. |
Anti-cd38 antibodies
|
|
CA3127660A1
(en)
|
2019-01-23 |
2020-07-30 |
Millennium Pharmaceuticals, Inc. |
Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
|
|
EP3982920A1
(en)
|
2019-06-14 |
2022-04-20 |
Zealand Pharma A/S |
Pharmaceutical parenteral composition of dual glp1/2 agonist
|
|
CN114630836A
(zh)
|
2019-08-27 |
2022-06-14 |
西兰制药第三特殊目的公司 |
补体抑制素类似物及其医学用途
|
|
US11918649B2
(en)
|
2019-09-18 |
2024-03-05 |
Molecular Templates, Inc. |
PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
|
|
TW202116350A
(zh)
|
2019-09-20 |
2021-05-01 |
丹麥商西蘭製藥公司 |
Kv1.3阻斷劑
|
|
US20210155671A1
(en)
|
2019-11-24 |
2021-05-27 |
Molecular Templates, Inc. |
Uses of cd20-binding molecules and additional therapeutic agents
|
|
US20230129788A1
(en)
|
2020-03-30 |
2023-04-27 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
US20230110689A1
(en)
|
2020-03-30 |
2023-04-13 |
Zealand Pharma A/S |
Agonist combination
|
|
CN116209671A
(zh)
|
2020-07-16 |
2023-06-02 |
西兰制药第三特殊目的公司 |
补体因子c3的抑制剂及其医学用途
|
|
WO2022103769A1
(en)
|
2020-11-11 |
2022-05-19 |
Ossianix, Inc. |
High affinity human and monkey specific tfr-1 vnars
|
|
TW202241491A
(zh)
|
2020-12-16 |
2022-11-01 |
丹麥商西蘭製藥公司 |
Glp-1/glp-2雙重促效劑之醫藥組合物
|
|
WO2022129311A1
(en)
|
2020-12-16 |
2022-06-23 |
Zealand Pharma A/S |
Pharmaceutical composition of glp-1/glp-2 dual agonists
|
|
US20240299552A1
(en)
|
2020-12-16 |
2024-09-12 |
Zealand Pharma A/S |
Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
|
|
US20240316155A1
(en)
|
2021-02-18 |
2024-09-26 |
Zealand Pharma A/S |
Composition for treating short bowel syndrome
|
|
WO2022197945A1
(en)
|
2021-03-17 |
2022-09-22 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
|
AU2022245193A1
(en)
|
2021-03-23 |
2023-09-07 |
Zealand Pharma A/S |
Kv1.3 blockers
|
|
WO2022260877A1
(en)
|
2021-06-07 |
2022-12-15 |
Ossianix, Inc. |
Shark vnars for treating covid-19
|
|
US20240279298A1
(en)
|
2021-06-18 |
2024-08-22 |
Beijing Tuo Jie Biopharmaceutical Co. Ltd. |
Glucagon analog and medical use thereof
|
|
US20250122298A1
(en)
|
2021-08-17 |
2025-04-17 |
Ossianix, Inc. |
Deimmunized vnar domains and scaffolds
|
|
JP2024533153A
(ja)
|
2021-09-03 |
2024-09-12 |
ジーランド ファーマ エー/エス |
投薬レジーム
|
|
EP4440592A1
(en)
|
2021-12-01 |
2024-10-09 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|
|
EP4604984A1
(en)
|
2022-10-18 |
2025-08-27 |
Zealand Pharma A/S |
Inhibitors
|
|
WO2024168411A1
(pt)
*
|
2023-02-15 |
2024-08-22 |
Proteimax Bio Technology Israel Ltd |
Aditivo de alimento e/ou suplemento alimentar, processo de obtenção, formulação de alimento funcional e/ou suplemento alimentar, uso
|
|
EP4471048A1
(en)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
EP4471049A1
(en)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
WO2025056677A1
(en)
|
2023-09-15 |
2025-03-20 |
Zealand Pharma A/S |
Dasiglucagon for use in the treatment of congenital hyperinsulinism
|
|
WO2025120002A1
(en)
|
2023-12-04 |
2025-06-12 |
Zealand Pharma A/S |
Petrelintide for reducing weight whilst preserving lean mass
|
|
TW202530247A
(zh)
|
2023-12-04 |
2025-08-01 |
丹麥商西蘭製藥公司 |
方法
|
|
WO2025248124A1
(en)
|
2024-05-31 |
2025-12-04 |
Zealand Pharma A/S |
Dapiglutide for use in treating a sub-group of subjects
|
|
WO2025259861A2
(en)
|
2024-06-12 |
2025-12-18 |
Invaio Sciences, Inc. |
Antimicrobial peptides against citrus greening
|
|
WO2025259842A2
(en)
|
2024-06-12 |
2025-12-18 |
Invaio Sciences, Inc. |
Novel alpha-factor based peptides with antifungal activity
|